EFTA02621262.pdf

From: Michael Kaplan ( ) Sent: Wednesday, October 3, 2018 3:25 PM To: [email protected] Subject: Announcing MRA's Next Chief Science Officer Dear Je=frey, <=:p> As a va=ued member of the Melanoma Research Alliance family and a generous contrib=tor to our work, I am writing to let you know about some exciting changes =ere at MRA that will be announced publicly tomorrow. It is w=th great enthusiasm that I share with you that Dr. Marc Hurlbert, Ph.D., w=ll join the MRA team on November 1st as our next Chief Science =fficer (CSO). Dr. Hurlbert comes to MRA with more than 15 years of experience leading programs to advance medi=al research and improve patient outcomes. We are confident he will be a tr=mendous asset to MRA and the fight against melanoma. &n=sp; A forma= announcement of Dr. Hurlbert's appointment will be made tomorrow. A= embargoed copy of the press statement is available <https://www.curemelanoma.oreassets/Uploads/MRA-Hurlbert-V3.pdf> . I would=also like to take this opportunity to thank Dr. Louise Perkins for her mor= than five years of service as MRA's Chief Science Officer. While ex=ited for her retirement, Louise has graciously agreed to continue with MRA in an advisory role through our 2019 grant rev=ew and Scientific Retreat. MRA would not be the organization it is without=Dr. Perkins. We are eternally grateful for her leadership, dedication and =een scientific insight. Please =oin me in wishing Louise a joyous retirement and in welcoming Marc to the =RA family. &n=sp; &n=sp; Michael Kaplan<=o:p> President & CEO=o:p> (202) 3=6.8939 P I 1101 New York Ave.,=NW, Ste. 620 EFTA_R1_01828098 EFTA02621262 Washington, DC 2000= &=bsp; www.curemelanoma.org chttp://www.curemelanoma.org> &n=sp; 2 EFTA_R1_01828099 EFTA02621263